Показано 0 из 0
Дата |
---|
18:38 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
18.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
7.98
|
8.72
|
7.98
|
7.98
|
7.98
|
7.98
|
|
|
|
|
7.98
|
8.74
|
8.08
|
7.98
|
8.08
|
7.98
|
|
|
|
|
8.14
|
8.72
|
8.08
|
8.08
|
8.14
|
8.14
|
|
|
|
|
7.98
|
8.74
|
7.86
|
7.86
|
8.00
|
7.98
|
|
|
|
|
8.02
|
8.74
|
8.00
|
8.00
|
8.02
|
8.02
|
|
|
|
|
8.02
|
8.74
|
8.18
|
8.02
|
8.18
|
8.02
|
|
|
|
|
8.30
|
8.74
|
8.24
|
8.24
|
8.30
|
8.30
|
|
|
132.48
|
6.00
|
8.20
|
8.76
|
8.18
|
8.18
|
8.20
|
8.20
|
|
|
|
|
8.18
|
8.80
|
8.08
|
8.08
|
8.18
|
8.18
|
|
|
|
|
8.08
|
8.80
|
8.04
|
8.04
|
8.28
|
8.08
|
|
|
1 318.40
|
6.00
|
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provide patients with various treatment options. Its pipeline is protected by a portfolio of patents and comprises three principal drug candidates that are in various stages of development.